Home The Word Brain My Amedeo FAQ Privacy About   


C49 + CC Journal Club

For more information, please refer to our special emails from April 13 and May 19.

  Ovarian Neoplasms

  Free Subscription


21.04.2025

1 BMC Cancer
1 Cancer Res
1 Clin Cancer Res
8 Gynecol Oncol
1 Oncogene
2 Oncol Rep


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    BMC Cancer

  1. TIAN L, Gao Y, Zi L, Zhe R, et al
    Dual Cas12a and multiplex crRNA CRISPR strategy ultrasensitive detection novel circRNA biomarker for the diagnosis of ovarian cancer.
    BMC Cancer. 2025;25:695.
    PubMed         Abstract available


    Cancer Res

  2. ZHANG C, Wang Y, He M, Wang C, et al
    Mannose Enhances Immunotherapy Efficacy in Ovarian Cancer by Modulating Gut Microbial Metabolites.
    Cancer Res. 2025 Apr 17. doi: 10.1158/0008-5472.CAN-24-3209.
    PubMed         Abstract available


    Clin Cancer Res

  3. KAAKS R, Cooley V, Mukama T, Teras LR, et al
    A Prospective Study Consortium for the Discovery and Validation of Early Detection Markers for Ovarian Cancer ("PREDICT") - Baseline findings for CA125.
    Clin Cancer Res. 2025 Apr 14. doi: 10.1158/1078-0432.CCR-24-1845.
    PubMed         Abstract available


    Gynecol Oncol

  4. WILKE RN, Wu CF, Kanbergs A, Bercow AS, et al
    Disparities in facility-level adoption of minimally invasive interval debulking surgery for advanced ovarian cancer.
    Gynecol Oncol. 2025;197:11-18.
    PubMed         Abstract available

  5. HERZOG TJ, Liao JB, Finkelstein K, Willmott L, et al
    An open-label randomized active-controlled phase II clinical study to assess the efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer (PROFECTA-II/GOG-3044).
    Gynecol Oncol. 2025;194:145-152.
    PubMed         Abstract available

  6. LI J, Welte T, Calzoncinth K, Vuttaradhi VK, et al
    An inducible FOXL2-dependent mouse model of ovarian adult type granulosa cell tumor.
    Gynecol Oncol. 2025;194:125-130.
    PubMed         Abstract available

  7. ASARE A, Previs RA, Spinosa D, Fellman B, et al
    Bevacizumab beyond progression: Impact of subsequent bevacizumab re-treatment in patients with ovarian, fallopian tube, and peritoneal cancer after progression.
    Gynecol Oncol. 2025;194:112-118.
    PubMed         Abstract available

  8. MATSUO K, Agarwal J, Chen L, Furey KB, et al
    Histology-specific prognostic significance of isolated tumor cells, micrometastases, and macrometastases in endometrial cancer.
    Gynecol Oncol. 2025;194:51-59.
    PubMed         Abstract available

  9. CORTES-SALGADO A, Moreno-Moreno E, Carretero-Barrio I, Caniego-Casas T, et al
    HER2 expression in a molecularly defined cohort of endometrial cancer patients: The SPECTRUM study.
    Gynecol Oncol. 2025;194:33-40.
    PubMed         Abstract available

  10. VALENZA C, Mongillo M, Visconti MV, Katrini J, et al
    Rechallenge with platinum-based chemotherapy in patients with platinum-resistant ovarian carcinoma: A cohort study.
    Gynecol Oncol. 2025;194:11-17.
    PubMed         Abstract available

  11. ZANNONI GF, Angelico G, Spadola S, Bragantini E, et al
    Chemotherapy Response Score (CRS): A comprehensive review of its prognostic and predictive value in High-Grade Serous Carcinoma (HGSC).
    Gynecol Oncol. 2025;194:1-10.
    PubMed         Abstract available


    Oncogene

  12. LI Y, Chen Z, Gao Y, Liu Y, et al
    SNRPB-mediated regulation of DDX39A splicing promotes ovarian cancer progression by regulating alpha6 integrin subunit expression.
    Oncogene. 2025 Apr 11. doi: 10.1038/s41388-025-03386.
    PubMed         Abstract available


    Oncol Rep

  13. YANG J, He R, Zhang X, Wang X, et al
    KLC3 activates PI3K/AKT signaling and promotes ovarian cancer cell proliferation and migration through COL3A1.
    Oncol Rep. 2025;53:67.
    PubMed         Abstract available

  14. SHEN K, Yuan S, Su N, Tang F, et al
    Monotherapy and combination therapy using antibody?drug conjugates for platinum?resistant ovarian cancer.
    Oncol Rep. 2025;53:68.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.